Amwill Healthcare Limited IPO

Apply 0
Avoid 0

The company are a specialized derma-cosmetic development company focused on creating problem-solving dermatological, cosmeceutical, and aesthetic products. Their business model is built around contract manufacturing, distribution partnerships, and third-party product development, allowing them to leverage external expertise in manufacturing, packaging, and distribution while we concentrate on product formulation and innovation.

Business Model and Strategy

i. Outsourcing Key Functions: Manufacturing, prototype development, and distribution are handled by third-party partners to ensure efficient execution.
ii. Regional Market Penetration: They have established a business presence in Karnataka, Andhra Pradesh, and Telangana, with a focus on strengthening their market presence before expanding to new territories.
iii. Product Development Focus: They develop both generic dermatological solutions and customized solutions for specific dermatological problems.

Product Portfolio and Development

Since incorporation, they have launched seven new products, including:
i. Proputor Tabs                                    ii. XL Hydra Cream                                   iii. Ozederm Cream
iv. PD-Pill 10 Tablets                            v. XL Aqua Moisturising Lotion             vi. Ultra Kromaglo Effervescent Tablets
vii. Depimed Ultra Cream

Conclusion

By integrating industry expertise, third-party partnerships, and medical collaborations, they have positioned themselves as a scientific and solution-oriented player in the derma-cosmetic industry. Their continued focus on innovation, customer-centric formulations, and strategic regional expansion is key to their growth and market presence.

Objects of the Amwill Healthcare Limited IPO:

The company proposes to utilize the Net Proceeds in the following manner. i. Funding of working capital requirements of the Company ii. Marketing and brand-building activities iii. General corporate purposes. Total number of shares issue :- i. Fresh issue is 44,03,600 shares, ii. Offer for sale is 10,00,000 shares.
DRHP of Amwill Healthcare Limited IPO
RHP of Amwill Healthcare Limited IPO

Amwill Healthcare Limited IPO Details:

Open Date: Feb 05 2025
Close Date: Feb 07 2025
Total Shares: 54,03,600
Face Value: ₹ 10 Per Equity Share
Issue Size: 59.98 Cr.
Lot Size: 1200 Shares
Issue Price: ₹ 105 - 111 Per Equity Share
Listing At: BSE SME
Listing Date: Feb 12 2025

Promoters And Management:

Tarun Gandhi, 39, is the Promoter, Chairman, and Managing Director of the Company. A commerce graduate from Bangalore University, he has over a decade of experience in finance, accounts, and business development. Previously, he managed purchase and finance at M/s. Amwill Healthcare before transitioning to the Company, where he became Managing Director on January 27, 2024. He currently oversees product development, business growth, and finance and is also a partner in Amderma Healthcare LLP, Ample Pharma, and Ayodhya Heritage Developers LLP. Anand Gandhi, 40, is the Promoter and Managing Director of the Company. A pharmacy graduate and post-graduate from Rajiv Gandhi University of Health Sciences, he previously owned M/s. Amwill Healthcare, managing its marketing and sales. After transferring the business, he became a Director and was later appointed Managing Director on January 27, 2024. With over a decade of experience in brand placement, marketing, and sales in dermatology, he now leads the marketing, sales, and dermatologist relations. He is also a partner in Amderma Healthcare LLP, Ample Pharma, and Ayodhya Heritage Developers LLP. Rekha Jagadish, 45, is a Non-Executive Director of the Company. A dental surgeon with a master’s in periodontics from Rajiv Gandhi University of Health Sciences, she has over a decade of experience as a medical professional and lecturer. She is a reader at Rajya Vokkaligara Sangha Dental College & Hospital and the sole proprietor of Skin Care Pharma, a dermatology-focused pharmacy business. Additionally, she is a partner at Roots Associates, which organizes industry conferences. She has been associated with the Company since December 28, 2023.

Financials of Amwill Healthcare Limited IPO:

(In Crores)
Particulars Sep 30, 2024 March 31, 2024 March 31, 2023 March 31, 2022
Revenue from Operations 23.15 43.94 30.16 27.61
EBITDA 8.83 16.66 4.29 3.66
EBITDA Margins 38.17% 37.92% 14.24% 13.25%
PAT 6.51 12.53 3.11 2.57
PAT Margins 28.14% 28.53% 10.32% 9.32%
ROCE 94.16% 83.32% 204.08%
CFOA 10.14 -3.05 4.79 3.01

Comparison With Peers:

Companies Revenue EBITDA Margins PAT Margins D/E Ratio MCap P/E
Amwill Health Care  (FY 2024) 43.94 Cr. 37.92% 28.53% - 222 Cr. 17.72
Vaishali Pharma (TTM) 99.17 Cr. 0.94% 1.10% 0.19 183 Cr. 167
Trident Lifeline (TTM) 66 Cr. 24% 18% 0.15 287 Cr. 24.20
Peers are primarily in the pharmaceutical sector, whereas Amwill operates in the cosmetics sector.

Recommendation on Amwill Healthcare Limited IPO:

Review and Recommendation of Amwill Healthcare IPO by team IZ is 4/10.

Lead Manager of Amwill Healthcare Limited IPO:

  1. Unistone Capital Pvt Ltd

Registrar of Amwill Healthcare Limited IPO:

  1. Bigshare Services Private Limited

Company Address:

Amwill Healthcare Limited No. 157, 1st Floor, 2nd Main, r, 2nd Main, 3rd Cross Chamrajpet Bangalore – 560018 Phone: +91 8043026281 Email: amwill@amwillhealthcare.com Website: https://www.amwillhealthcare.com/

Discussion on Amwill Healthcare Limited IPO:

Leave a Reply